CuFe (ASX:CUF), Emmerson Resources (ASX:ERM) and Tennant Minerals (ASX:TMS) strategic Tennant Creek Copper Alliance has successfully been awarded grants totalling $600,000 from the Northern Territory and Federal Governments.

🤝 Alliance members to match funding for Feasibility Study
🏭 Multi-user minerals processing facility under study
📅 Study completion targeted June 2026

1414 Degrees (ASX:14D) has achieved the first significant technical performance milestone in its SiNTL™ silicon anode program, reaching 500 mAh/g capacity ahead of the commercialisation schedule.

🚀 SiNTL™ silicon anode achieved 500 mAh/g, reaching its first development milestone ahead of schedule
⚡ Performance matches current best-in-class commercial silicon anodes, validating the material design
📈 Clear pathway to 600 mAh/g defined, targeting around 20% above current commercial benchmarks
🏭 Low-temperature, scalable synthesis process compatible with existing anode manufacturing
🔬 Anode testing underway using SiPHyR™ graphitic carbon, creating potential downstream value
🌍 Positioned to capitalise on a rapidly growing silicon-anode market, forecast to exceed USD $20.8bn by 2034

“This milestone demonstrates that SiNTL is not just a research program; it is a commercial platform in development. As performance improves and scalability is validated, the strategic relevance of this technology to battery manufacturers and OEM supply chains becomes increasingly clear.” Dr Peter Yaron, 1414 Degrees Chief Technology & Operations Officer

“The performance data confirms that the silicon composite architecture and synthesis approach are delivering the electrochemical characteristics required for next-generation anode materials. The ability to systematically link material structure to battery performance is what enables predictable scaling and ongoing improvement, which is critical for commercial deployment.” Professor Michael Wagner, SiNTL inventor

Venari Minerals NL (ASX:VMS) has delivered a milestone with the release of its maiden Inferred Mineral Resource Estimate at the 100%-owned Red Mountain Lithium Project in Nevada, USA. The maiden Mineral Resource Estimate comes amid a sharp resurgence in lithium prices and growing forecasts of a global supply deficit. Venari Executive Director and CEO Matt Healy joins The Stock Network’s Lel Smits to discuss the significance of the maiden resource, how Red Mountain compares globally, and what’s next as the project moves into its next phase of advancement.

⛰️ Maiden MRE confirms scale and grade at Red Mountain
⛏️ High-grade core and open-ended growth potential
⚒️ Next steps: drilling, metallurgy and exploration momentum

Here’s why your future wealth depends on who you listen to. Most people don’t lose money because they pick bad investments, they lose money because they take advice from the wrong people. Mates with no track record, social media hype, and scary headlines don’t know your goals, your timeline, or how much risk you can actually handle.

Good advice is calm, boring, and consistent. It sticks to a plan, ignores the noise, and doesn’t change every time a new hot tip pops up. I’ve seen people completely derail solid strategies because of something they heard at a barbecue, only to spend years undoing the damage.

Brought to you by TSN education partner Link Wealth Advice
___
General advice disclaimer: This post is general in nature and doesn’t take into account your individual circumstances or goals. Everyone’s situation is different. If you want advice that’s tailored to you, please get in touch so we can talk about what’s right for you.

#WealthManagementhbuilding #financialadvice #investingsmart #moneymindset #australianfinance

With global interest in innovative drug delivery and radiopharmaceuticals accelerating, Starpharma (ASX:SPL, US OTC:SPHRY) continues to advance its strategy of advancing its proprietary DEP® dendrimer platform through a combination of strategic partnerships and internal pipeline development. Following a series of high-level meetings at the J.P. Morgan Healthcare Conference in California, and the release of its Q2 FY26 quarterly results, Starpharma CEO & Managing Director Cheryl Maley joins The Stock Network’s Lel Smits to discuss recent milestones, the significance of its Genentech collaboration, and what lies ahead for the DEP® platform.

🤝 Strategic partnerships driving momentum
🩻 Advancing radiopharmaceuticals and internal pipeline
⚕️ Business development and J.P. Morgan Healthcare Conference insights

Dateline Resources (ASX: DTR | OTCQB: DTREF) has released its December 2025 quarterly activities report, highlighting strong momentum at the Colosseum Gold-REE Project in California, USA. Highlights during the quarter include:

⛏️ Bankable Feasibility Study (BFS) on track for completion in Q1 2026, with key long-lead items identified, metallurgical testwork completed (91–92% recoveries), and access road upgrades finished
💧 Water rights and infrastructure secured, including 27 acres of land near the Colosseum Mine Road
🏗️ Potential cost and schedule savings identified through reuse of historical processing plant foundations
🪨 Extensive drilling success, delivering wide, near-surface gold intercepts and confirming mineralisation remains open at depth and to the northeast
📡 Induced Polarisation survey completed, delivering a high-quality subsurface dataset now under interpretation
👷‍♂️ Board strengthened with the appointment of experienced U.S. mining executives
📈 Balance sheet strengthened, with a $35 million placement increasing cash to ~$58 million

WAM Alternative Assets (ASX:WMA) invests across private equity, infrastructure, real assets, private debt and fixed income and ahead of presenting at Wholesale Investor`s Emergence 2026, Portfolio Manager, Nick Kelly speaks with The Stock Network’s Lel Smits about how alternative assets can play a powerful role in portfolios during periods of market uncertainty.

🌱 Diversification beyond traditional markets
🛡️ Identifying income resilience and capital protection

👉 Wholesale Investor`s Emergence 2026
🗓 18-20 February, 2026
📍 Four Seasons Hotel, Sydney

@reccepharma (ASX: RCE, FSE: R9Q) is a clinical-stage biotechnology company developing a new class of synthetic anti-infectives designed to address the growing global threat of antibiotic-resistant superbugs. Over the past year, Recce’s share price has risen more than 40% on the back of the company progressing its clinical pipeline and securing regulatory and funding milestones and ahead of presenting at @wholesaleinvestor`s Emergence 2026, Chief Executive Officer James Graham speaks with The Stock Network’s @lelsmits about what should investors be watching next as Recce progresses its anti-infective pipeline.

♥️ Addressing a critical global health problem
⚕️ Clinical progress, funding and value inflection points

👉 Wholesale Investor`s Emergence 2026
🗓 18-20 February, 2026
📍 Four Seasons Hotel, Sydney